Hizentra 200 mg/ml solution for subcutaneous injection, Human Albumin ”CSL Behring”, infusionsvæske, opløsning 5 % clinical trials

Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

This study looks at a medicine called IgPro20 (Hizentra®) for people who have POTS after COVID-19. It aims to see if the medicine can reduce symptoms and make people feel better, compared to a dummy treatment.